Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)~* Male or female patients at least 18 years of age at time of informed consent~* T1DM (diagnosed clinically) prior to inclusion in the study, and/or T2DM, insulin using patients (diagnosed clinically) prior to inclusion in the study~* Planned initiation with Tresiba®~Exclusion Criteria:~* Known or suspected hypersensitivity to Tresiba® or any of the excipients listed in Section 6.1 of the SmPC (Summary of Product Characteristics) or related products~* Previous participation in this study (i.e. provision of informed consent)~* Patients who have previously been treated with Tresiba®~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).